Novo Nordisk Hit With Antitrust Action Over Prandin

Law360, New York (June 1, 2010, 1:27 PM EDT) -- Novo Nordisk A/S has been slapped with a putative class action that accuses it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers.

American Sales Co. Inc., which purchases health products and prescription drugs for retail stores, filed the complaint Friday in the U.S. District Court for the Eastern District of Michigan.

The suit claims that Novo Nordisk has maintained an unlawful monopoly on the market for repaglinide — sold under the brand name Prandin in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.